Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas

BACKGROUND: The treatment goal for recurrent malignant gliomas centers on disease stabilization while minimizing therapy-related side effects. Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective. METHODS: This phase I study was performed using metr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Eric T., Timmons, Joshua, Callahan, Amy, O’Loughlin, Lauren, Giarusso, Bridget, Alsop, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120517/
https://www.ncbi.nlm.nih.gov/pubmed/27876012
http://dx.doi.org/10.1186/s12885-016-2945-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120517/
https://www.ncbi.nlm.nih.gov/pubmed/27876012
http://dx.doi.org/10.1186/s12885-016-2945-2

Ejemplares similares